The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Metformin in cancer
Abstract
Metformin is a lipophilic biguanide which inhibits hepatic gluconeogenesis and improves peripheral utilization of glucose. It is the first line pharmacotherapy for glucose control in patients with Type 2 diabetes due to its safety, efficacy and tolerability. Metformin exhibits pleotropic effects, which may have beneficial effects on a variety of tissues independent of glucose control. A potential anti-tumourigenic effect of metformin may be mediated by its role in activating AMP-kinase, which in turn inhibits mammalian target of rapamycin (mTOR). Non-AMPK dependent protective pathways may include reduction of insulin, insulin-like growth factor-1, leptin, inflammatory pathways and potentiation of adiponectin, all of which may have a role in tumourigenesis. A role in inhibiting cancer stem cells is also postulated. A number of large scale observational and cohort studies suggest metformin is associated with a reduced risk of a number of cancers, although the data is not conclusive. Recent randomised studies reporting use of metformin in treatment of cancer have revealed mixed results, and the results of much larger randomised trials of metformin as an adjuvant therapy in breast and colorectal cancers are awaited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Traditional Plant Medicines as Treatments for Diabetes
Bailey, C. J., & Day, C. (1989) · Diabetes Care · doi:10.2337/diacare.12.8.553 · Cited by 832
(2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70095-4 · Cited by 652
Wideroff, L., Gridley, G., Chow, W. H., Linet, M., Mellemkjaer, L., Olsen, J. H., Keehn, S., & Borch-Johnsen, K. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.18.1360 · Cited by 627
Immune-mediated antitumor effect by type 2 diabetes drug, metformin
Eikawa, S., Nishida, M., Mizukami, S., Yamazaki, C., Nakayama, E., & Udono, H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417636112 · Cited by 557
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Hirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418
The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator
Faubert, B., Vincent, E. E., Poffenberger, M. C., & Jones, R. G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.018 · Cited by 354
Prospective Study of Hyperglycemia and Cancer Risk
Stattin, P., Björ, O., Ferrari, P., Lukanova, A., Lenner, P., Lindahl, B., Hallmans, G., & Kaaks, R. (2007) · Diabetes Care · doi:10.2337/dc06-0922 · Cited by 352
Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
Pisani, P. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954451 · Cited by 329
Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Rocha, G. Z., Dias, M. M., Ropelle, E. R., Osório-Costa, F., Rossato, F. A., Vercesi, A. E., Saad, M. J. A., & Carvalheira, J. B. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2243 · Cited by 305
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Gunton, J. E., Delhanty, P. J. D., Takahashi, S.-I., & Baxter, R. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021394 · Cited by 234
He, X., Esteva, F. J., Ensor, J., Hortobagyi, G. N., Lee, M.-H., & Yeung, S.-C. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr534 · Cited by 207
Negrotto, L., Farez, M. F., & Correale, J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4807 · Cited by 198
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., Lopez, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 190
Risk of Cancer Following Hospitalization for Type 2 Diabetes
Hemminki, K., Li, X., Sundquist, J., & Sundquist, K. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0300 · Cited by 181
Vazquez-Martin, A., Oliveras-Ferraros, C., Barco, S. D., Martin-Castillo, B., & Menendez, J. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0924-x · Cited by 179
Wang, Z., Lai, S.-T., Xie, L., Zhao, J.-D., Ma, N.-Y., Zhu, J., Ren, Z.-G., & Jiang, G.-L. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.007 · Cited by 176
Kim, H. G., Hien, T. T., Han, E. H., Hwang, Y. P., Choi, J. H., Kang, K. W., Kwon, K., Kim, B., Kim, S. K., Song, G. Y., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01101.x · Cited by 172
Reni, M., Dugnani, E., Cereda, S., Belli, C., Balzano, G., Nicoletti, R., Liberati, D., Pasquale, V., Scavini, M., Maggiora, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1722 · Cited by 170
Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin
Takiyama, Y., Harumi, T., Watanabe, J., Fujita, Y., Honjo, J., Shimizu, N., Makino, Y., & Haneda, M. (2011) · Diabetes · doi:10.2337/db10-0655 · Cited by 169
Metformin: An anti-diabetic drug to fight cancer
Daugan, M., Dufaÿ Wojcicki, A., d’Hayer, B., & Boudy, V. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.006 · Cited by 164
STUDIES IN THE METABOLISM CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES
Watanabe, C. K. (1918) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86579-6 · Cited by 163
Argaud, D., Roth, H., Wiernsperger, N. F., & Leverve, X. M. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17886.x · Cited by 156
Orecchioni, S., Reggiani, F., Talarico, G., Mancuso, P., Calleri, A., Gregato, G., Labanca, V., Noonan, D. M., Dallaglio, K., Albini, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29193 · Cited by 155
Paradoxic effects of metformin on endothelial cells and angiogenesis
Dallaglio, K., Bruno, A., Cantelmo, A. R., Esposito, A. I., Ruggiero, L., Orecchioni, S., Calleri, A., Bertolini, F., Pfeffer, U., Noonan, D. M., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu001 · Cited by 149
Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
Forouzandeh, F., Salazar, G., Patrushev, N. A., Xiong, S., Hilenski, L. L., Fei, B., & Alexander, R. W. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001202 · Cited by 139
Ma, J., Sawai, H., Matsuo, Y., Ochi, N., Yasuda, A., Takahashi, H., Wakasugi, T., Funahashi, H., Sato, M., & Takeyama, H. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2008.08.016 · Cited by 138
Serum Levels of Leptin, Insulin, and Lipids in Relation to Breast Cancer in China
Han, C., Zhang, H., Du, L., Liu, X., Jing, J., Zhao, X., Yang, X., & Tian, B. (2005) · Endocrine · doi:10.1385/endo:26:1:019 · Cited by 133
Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer
Chen, K., Qian, W., Jiang, Z., Cheng, L., Li, J., Sun, L., Zhou, C., Gao, L., Lei, M., Yan, B., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0701-0 · Cited by 126
Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells
Giudicelli (1994) · Oncology Reports · doi:10.3892/or_00000098 · Cited by 123
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
Meireles, C. G., Pereira, S. A., Valadares, L. P., Rêgo, D. F., Simeoni, L. A., Guerra, E. N. S., & Lofrano‐Porto, A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.120 · Cited by 122
Cicero, A. F. G., Tartagni, E., & Ertek, S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31622 · Cited by 114
Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153
WU, N., GU, C., GU, H., Hu, H., Han, Y., & Li, Q. (2011) · Neoplasma · doi:10.4149/neo_2011_06_482 · Cited by 113
Antileukemic effects of AMPK activators on BCR-ABL–expressing cells
Vakana, E., Altman, J. K., Glaser, H., Donato, N. J., & Platanias, L. C. (2011) · Blood · doi:10.1182/blood-2011-01-332783 · Cited by 104
Takemura, Y., Osuga, Y., Yoshino, O., Hasegawa, A., Hirata, T., Hirota, Y., Nose, E., Morimoto, C., Harada, M., Koga, K., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2486 · Cited by 103
Liu, F., Yan, L., Wang, Z., Lu, Y., Chu, Y., Li, X., Liu, Y., Rui, D., Nie, S., & Xiang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.13762 · Cited by 99
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89
Krishan, S., Richardson, D. R., & Sahni, S. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095810 · Cited by 88
Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response
Vazquez-Martin, A., Oliveras-Ferraros, C., Cufí, S., Martin-Castillo, B., & Menendez, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15423 · Cited by 81
Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes
Tseng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109852 · Cited by 80
Shafiei‐Irannejad, V., Samadi, N., Yousefi, B., Salehi, R., Velaei, K., & Zarghami, N. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13078 · Cited by 80
Chowdhury, T. A. (2010) · QJM · doi:10.1093/qjmed/hcq149 · Cited by 78
Self-citationThe effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
Li, X., Li, T., Liu, Z., Gou, S., & Wang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06207-x · Cited by 78
Irreversible Lactic Acidosis Associated With Phenformin Therapy: Report of Three Cases
Tranquada, R. E., Bernstein, S. J., & Martin, H. L. (1963) · JAMA · doi:10.1001/jama.1963.03700140093013 · Cited by 77
Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies
Yousef, M., & Tsiani, E. (2017) · Cancers · doi:10.3390/cancers9050045 · Cited by 77
Morgillo, F., Fasano, M., Della Corte, C. M., Sasso, F. C., Papaccio, F., Viscardi, G., Esposito, G., Di Liello, R., Normanno, N., Capuano, A., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000132 · Cited by 76
Metformin inhibits inflammatory angiogenesis in a murine sponge model
Xavier, D. O., Amaral, L. S. D. B., Gomes, M. A., Rocha, M. A., Campos, P. R., Cota, B. D. C. V., Tafuri, L., Paiva, A., Silva, J. H., Andrade, S. P., et al. (2009) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2009.08.004 · Cited by 71
Wang, Y., Liu, G., Tong, D., Parmar, H., Hasenmayer, D., Yuan, W., Zhang, D., & Jiang, J. (2015) · The Prostate · doi:10.1002/pros.23000 · Cited by 70
Sayed, R., Saad, A. S., Wakeel, L. M. E., Elkholy, E., & Badary, O. A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.15.6621 · Cited by 63
Chen, X., Li, C., He, T., Mao, J., Li, C., Lyu, J., & Meng, Q. H. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1156273 · Cited by 60
Metformin therapy associated with survival benefit in lung cancer patients with diabetes
Wan, G., Yu, X., Chen, P., Wang, X., Pan, D., Wang, X., Li, L., Cai, X., & Cao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.8881 · Cited by 59
Zhang, J., Li, G., Chen, Y., Fang, L., Chen, G., Bai, F., Ma, M., Lyu, J., & Meng, Q. H. (2017) · Journal of Cancer · doi:10.7150/jca.19858 · Cited by 58
Yang, T., Yang, Y., & Liu, S. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.264 · Cited by 57
Tadakawa, M., Takeda, T., Li, B., Tsuiji, K., & Yaegashi, N. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.08.012 · Cited by 56
Tian, R., Zhang, Y.-G., Wu, Z., Liu, X., Yang, J.-W., & Ji, H. L. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1412-x · Cited by 55
Haring, A., Murtola, T. J., Talala, K. M., Taari, K., Tammela, T. L. J., & Auvinen, A. P. (2017) · Scandinavian Journal of Urology · doi:10.1080/21681805.2016.1271353 · Cited by 52
STUDIES IN THE METABOLIC CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES
Watanabe, C. K. (1918) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)86531-0 · Cited by 51
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis
Jung, Y. S., Park, C. H., Eun, C. S., Park, D. I., & Han, D. S. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13639 · Cited by 49
Park, J., Lee, J. H., Park, Y., Park, S. J., Cheon, J. H., Kim, W. H., & Kim, T. I. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i28.5196 · Cited by 47
Lin, J., Gill, A. A., Zahm, S. H., Carter, C. A., Shriver, C. D., Nations, J. A., Anderson, W. F., McGlynn, K. A., & Zhu, K. (2017) · International Journal of Cancer · doi:10.1002/ijc.30724 · Cited by 46
Wang, S., Lei, K., Liu, J., & Jia, Y. (2017) · Medicine · doi:10.1097/md.0000000000007605 · Cited by 46
Lettieri‐Barbato, D., Vegliante, R., Desideri, E., & Ciriolo, M. R. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.02.003 · Cited by 42
Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis
Zhu, N., Zhang, Y., Gong, Y., He, J., & CHEN, X. (2015) · Biomedical Reports · doi:10.3892/br.2015.417 · Cited by 41
Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells
Lee, J., Park, D., & Lee, Y. (2017) · Development & Reproduction · doi:10.12717/dr.2017.21.2.139 · Cited by 40
Guo, Z., Zhao, M., Howard, E. W., Zhao, Q., Parris, A. B., Ma, Z., & Yang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.19466 · Cited by 39
The impact of metformin use on survival in kidney cancer patients with diabetes: A meta-analysis
Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1548-4 · Cited by 38
Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study
Feng, T., Sun, X., Howard, L. E., Vidal, A. C., Freedland, A. R., Moreira, D. M., Castro‐Santamaria, R., Andriole, G. L., & Freedland, S. J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0141 · Cited by 37
Adam, W. R., & O’Brien, R. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12515 · Cited by 34
Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Cas, A. D., Spigoni, V., Ridolfi, V., et al. (2013) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530311313010006 · Cited by 33
Du, L., Wang, M., Kang, Y., Li, B., Guo, M., Cheng, Z., & Bi, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14688 · Cited by 32
Hadad, S. M., Appleyard, V. C. L., & Thompson, A. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0016-3 · Cited by 31
[Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)].
Sterne, J. (1959) · PubMed · Cited by 31
Metformin and Breast Cancer Stage at Diagnosis: A Population-Based Study
Lega, I. C., Fung, K., Austin, P. C., & Lipscombe, L. L. (2017) · Current Oncology · doi:10.3747/co.24.3380 · Cited by 25
Nguyen, M. M., Martinez, J. A., Hsu, C.-H., Sokoloff, M., Krouse, R. S., Gibson, B. A., Nagle, R. B., Parnes, H. L., Cordova, C. A., & Chow, H. ‐. S. (2017) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000394 · Cited by 23
Abo–Elmatty, D. M., Ahmed, E., Tawfik, M. K., & Helmy, S. A. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.002 · Cited by 22
Wang, Y., Wu, Z., & Hu, L. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/2520581 · Cited by 22
Nie, S., Chen, H., Zhuang, M., & Lü, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.16.6863 · Cited by 21
Crawley, D., Chandra, A., Loda, M. F., Gillett, C., Cathcart, P. J., Challacombe, B. J., Cook, G., Cahill, D. J., Olalla, A. S., Cahill, F., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3458-3 · Cited by 19
Cited by
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Role of mitochondria in the mechanism(s) of action of metformin
Vial, G., Detaille, D., & Guigas, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00294 · Cited by 303
Serine, glycine and one‑carbon metabolism in cancer (Review)
Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227
Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer
Samuel, S. M., Varghese, E., Varghese, S., & Büsselberg, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.004 · Cited by 141
Metadata
- Authors
- Mallik, R., & Chowdhury, T. A.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 143
- Pages
- 409-419
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2804416221
- Cited by
- 260
- References
- 92
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.